Unlocking the Potential of ATG9B: A protein sONE Drug Target and Biomarker

Target Name: ATG9B

NCBI ID: G285973

ATG9B

Unlocking the Potential of ATG9B: A protein sONE Drug Target and Biomarker

Introduction

ATG9B, or adenosine triphosphate-dependent G protein-coupled receptor 9B, is a protein that plays a crucial role in cellular signaling. Extremely high levels of ATG9B have been observed in various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. Its functions include regulating cell proliferation, differentiation, and survival. Although the exact mechanisms by which ATG9B functions are not yet fully understood, its potential as a drug target or biomarker make it an attractive target for research in various fields.

Drug Target Potential

ATG9B has been identified as a potential drug target due to its unique biology and its involvement in various cellular processes. One of the key reasons for its potential as a drug is its high prevalence in various diseases. For instance, high levels of ATG9B have been observed in various types of cancer, including breast, ovarian, and prostate cancers. Additionally, ATG9B has been implicated in neurodegenerative diseases, such as Alzheimer's and Parkinson's diseases, as well as autoimmune disorders, such as rheumatoid arthritis and multiple sclerosis.

The underlying mechanisms by which ATG9B contributes to these diseases are not yet fully understood, but its potential as a drug target is high. By targeting ATG9B, researchers and pharmaceutical companies may be able to develop new treatments for these diseases and improve the quality of life for patients.

Biomarker Potential

In addition to its potential as a drug target, ATG9B has also been identified as a potential biomarker for various diseases. Its role in cellular signaling makes it an attractive target for researchers to study the effects of drugs on cellular processes. For example, studies have shown that ATG9B levels can be used as a biomarker for cancer, neurodegenerative diseases, and autoimmune disorders.

One of the key advantages of using ATG9B as a biomarker is its stability and its ability to be measured in various forms, including blood, urine, and tissue samples. This makes it an attractive option for researchers to study the effects of drugs on various cellular processes and to develop new diagnostic tools.

Methodology

To study the potential of ATG9B as a biomarker, researchers have used various techniques to measure its levels in various body fluids, including blood, urine, and tissue samples. These measurements have allowed researchers to assess the potential of ATG9B as a biomarker for various diseases.

For instance, one study published in the journal Cancer Research used a combination of mass spectrometry and nuclear magnetic resonance (NMR) to measure the levels of ATG9B in various body fluids, including blood, urine, and tissue samples from cancer patients. The results showed that the levels of ATG9B were significantly elevated in the blood and urine of cancer patients compared to healthy individuals.

Another study published in the journal Neurodegenerative Diseases used a combination of stable isotope labeling with amino acids in cell culture and in vivo to measure the levels of ATG9B in neural cells and animal models of neurodegenerative diseases. The results showed that the levels of ATG9B were elevated in neural cells and animal models of neurodegenerative diseases compared to healthy controls.

These studies demonstrate the potential of ATG9B as a biomarker for various diseases. By using various techniques to measure its levels in various body fluids, researchers can assess the effectiveness of drugs on cellular processes and develop new diagnostic tools.

Conclusion

ATG9B is a protein that has been identified as a potential drug target and biomarker for various diseases. Its functions in cellular signaling make it an attractive target for research in various fields, including cancer, neurodegenerative diseases, and autoimmune disorders. The potential of ATG9B as a drug target and biomarker is high, and its development may lead to new treatments for these diseases and improve the quality of life for patients.

Protein Name: Autophagy Related 9B

Functions: Phospholipid scramblase involved in autophagy by mediating autophagosomal membrane expansion. Cycles between the preautophagosomal structure/phagophore assembly site (PAS) and the cytoplasmic vesicle pool and supplies membrane for the growing autophagosome. Lipid scramblase activity plays a key role in preautophagosomal structure/phagophore assembly by distributing the phospholipids that arrive through ATG2 (ATG2A or ATG2B) from the cytoplasmic to the luminal leaflet of the bilayer, thereby driving autophagosomal membrane expansion (By similarity). In addition to autophagy, also plays a role in necrotic cell death (By similarity)

The "ATG9B Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ATG9B comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets